2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin’s and Non-Hodgkin Lymphomas

Uloženo v:
Podrobná bibliografie
Název: 2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin’s and Non-Hodgkin Lymphomas
Autoři: Withofs, Nadia, Bonnet, Christophe, Hustinx, Roland
Zdroj: PET Clinics. 19:447-462
Informace o vydavateli: Elsevier BV, 2024.
Rok vydání: 2024
Témata: Radiology, Nuclear Medicine and Imaging, Radiation, Lymphoma, Hodgkin Disease/diagnostic imaging, Lymphoma, Non-Hodgkin, Lymphoma, Non-Hodgkin/diagnostic imaging, Radiologie, médecine & imagerie nucléaire, Assessment, Positron-Emission Tomography/methods, Sciences de la santé humaine, Hodgkin Disease, Adapted, PET, Hodgkin, Fluorodeoxyglucose F18, DLBCL, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography, Humans, Therapy, Human health sciences, Radiopharmaceuticals, Positron Emission Tomography Computed Tomography/methods, Radiology, nuclear medicine & imaging, Neoplasm Staging
Popis: The 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography combined with computed tomography (PET/CT) has contributed to outcome improvement of patients with lymphoma. The use of [18F]FDG PET/CT for staging and response assessment is successfully applied both in routine clinical practice and in clinical trials. The challenges lie in enhancing the outcomes of lymphoma patients, particularly those with advanced or refractory/relapsed disease, and to minimize the long-term toxicity associated with treatments, including radiation therapy. The objective of this review article is to present contemporary data on the use of [18F]FDG PET/CT for treatment assessment of aggressive lymphomas.
Druh dokumentu: Article
Jazyk: English
ISSN: 1556-8598
DOI: 10.1016/j.cpet.2024.05.001
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38945737
Rights: Elsevier TDM
Přístupové číslo: edsair.doi.dedup.....1f2832656e8070f0d0f008773c3e92d2
Databáze: OpenAIRE
Popis
Abstrakt:The 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography combined with computed tomography (PET/CT) has contributed to outcome improvement of patients with lymphoma. The use of [18F]FDG PET/CT for staging and response assessment is successfully applied both in routine clinical practice and in clinical trials. The challenges lie in enhancing the outcomes of lymphoma patients, particularly those with advanced or refractory/relapsed disease, and to minimize the long-term toxicity associated with treatments, including radiation therapy. The objective of this review article is to present contemporary data on the use of [18F]FDG PET/CT for treatment assessment of aggressive lymphomas.
ISSN:15568598
DOI:10.1016/j.cpet.2024.05.001